大型国际肿瘤患者围手术期护理随机对照试验的招募模式
PARITY试验是首个在多个国际中心前瞻性入组并随机化骨科肿瘤患者的随机对照试验。研究描述了36个北美和12个国际中心的招募模式,比较了不同中心特征(地区、医疗模式、科研人员支持)对招募速度和启动时间的影响。结果显示国际中心启动较慢但入组后月招募率更高,有科研支持的中心启动更快。
要点
- 国际中心启动时间较长(平均27个月)但入组后月招募率更高(0.59 vs 0.2例/月)。
- 有科研支持的中心启动更快(19.3 vs 30.3个月)且入组后月招募率更高(0.28 vs 0.2例/月)。
- 公立中心月入组率高于私立中心(0.4 vs 0.17例/月)。
核心结论
- PARITY试验通过增加活跃中心数量加快了整体招募速度。
- 国际中心启动较慢可能源于药物试验的复杂法规,但入组后月招募量显著更高,应被视为关键参与方。
- 缺乏科研支持人员可能导致启动延迟。
研究设计与样本
- 研究基于PARITY随机对照试验(NCT01479283)的方法中心数据及与招募中心的通信记录。
- 共纳入来自36个北美中心和12个国际中心的602例患者,招募时间为2013年至2019年。
- 采用描述性统计报告招募模式,并用双尾非配对t检验比较组间平均月招募率。
主要发现
- 北美中心平均19.5个月达到完全可入组状态,国际中心平均27个月。
- 入组后国际中心月招募率为0.59例/月,北美中心为0.2例/月。
- 有科研支持的中心平均19.3个月达到可入组状态,无支持的中心为30.3个月。
- 入组后月招募率在有科研支持的中心为0.28例/月,无支持的中心为0.2例/月。
- 公立中心月入组率为0.4例/月,私立中心为0.17例/月。
临床怎么用
- 未来骨科肿瘤及其他外科专科的协作临床试验选择中心时,可参考启动时间、科研支持及机构类型对招募的影响。
- 应优先考虑具备科研支持人员的中心以缩短启动时间。
- 国际中心虽启动慢,但入组后招募效率高,仍应纳入试验网络。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) randomized controlled trial (RCT) was the first study to prospectively enroll and randomize orthopedic oncology patients in multiple centers internationally. The objective of this study was to describe recruitment patterns, to examine the differences in enrollment across different PARITY sites, and to identify variables associated with differing levels of recruitment. METHODS: Data from this study was obtained from the PARITY trial Methods Center and records of correspondence between the Methods Center and recruiting sites. We performed descriptive statistics to report the recruitment patterns over time. We compared recruitment, time to set up, and time to enroll the first patient between North American and international sites, private and public healthcare models, and the presence or absence of research personnel. Two-tailed non-paired t tests were performed to test average monthly recruitment rates between groups. RESULTS: A total of 602 patients from 36 North American and 12 international sites were recruited from 2013 to 2019. North American sites were able to become fully enrollment-ready at an average of 19.5 months and international sites at an average of 27 months. Once enrolling, international sites were able to enroll 0.59 patients per/month whereas North American sites averaged a monthly recruitment rate of 0.2 patients/month once enrolling. Sites with research personnel reached enrollment-ready status at an average of 19.3 months and sites without research support at an average of 30.3 months. Once enrolling, the recruitment rate was 0.28 patients/month and 0.2 patients per month for sites with and without research support, respectively. Publicly funded sites had a monthly enrollment of 0.4 patients/month whereas privately funded sites had a monthly enrollment rate of 0.17 patients/month. CONCLUSIONS: As a collaborative group, the PARITY investigators increased the pace of recruitment throughout the trial, likely by increasing the number of active sites. The longer time to start-up at international sites may be due to the complex governing regulations of pharmaceutical trials. Nevertheless, international sites should be considered essential as they recruited significantly more patients per month once active. The absence of research support personnel may lead to delays in the time to start-up. The results of the current study will provide guidance for choosing which sites to recruit for participation in future collaborative clinical trials in orthopedic oncology and other surgical specialties. TRIAL REGISTRATION: ClinicalTrials.gov NCT01479283 . Prospectively registered on November 24, 2011.
引用
- Gazendam A, Bozzo A, Schneider P, et al. Recruitment patterns in a large international randomized controlled trial of perioperative care in cancer patients. Trials. 2021. PMID: 33743753. doi:10.1186/s13063-021-05149-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。